McKesson Corporation Common Stock (MCK)
Stock · NYSE · Health Care
$1,005as of 10/16/2026
Price chart
Active signals
MCK Signal Track Record
How signals performed across all stocks →What MCK's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakout | 34 | +1.8% | 65% | September 2, 2026 |
| Volume Spike | 32 | +2.0% | 66% | September 4, 2026 |
| Bollinger Band Breakdown | 13 | -0.3% | 46% | May 6, 2026 |
| 200-Day Moving Average TouchActive now | 8 | +3.8% | 75% | September 30, 2026 |
| Any 20-session window (baseline) | +2.1% | 64% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to r…
- Sector
- Health Care
- Industry
- Other Pharmaceuticals
- Employees
- 41,600
- Website
- www.mckesson.com/
Fundamentals
- 1-day range
- $988.61$1,003
- Market cap
- $104.74B
- P/E (trailing)
- 25.30
- P/E (forward)
- 19.75
- EPS (trailing)
- $37.35
- Dividend yield
- 0.54%
- Beta
- 0.31
- Avg. volume
- 904.7K
- Ex-dividend date
- September 1, 2026
- Dividend pay date
- October 1, 2026
How McKesson Corporation Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed May 8, 2026 · via SEC EDGAR / Finnhub
Forecasts
14 analyst ratings
McKesson Corporation Common Stock Competitors
Chosen by industry and closest market cap.
- MCKMcKesson Corporation Common Stock$1,005▲ 0.62%Market cap $104.74BP/E 25.30$723.68$999
- CORCencora Inc. Common Stock$340.92▼ 0.14%Market cap $63.23BP/E 24.39$244.82$377.54
- CAHCardinal Health Inc. Common Stock$254.06▲ 0.14%Market cap $55.66BP/E 33.97$152.46$258.3
- HLFHerbalife Ltd. Common Shares$14.6▲ 0.21%Market cap $1.19BP/E 9.24$7.56$20.4
- NUSNu Skin Enterprises Inc. Common Stock$5.14▼ 1.34%Market cap $251.98MP/E 4.30$4.45$11.67
- ZSTKZeroStack Corp. Common Stock$4▼ 5.21%Market cap $30.78MP/E —$1.32$20.45
- HKPDCellyan Biotechnology Co. Ltd Class A Ordinary Shares$0.11▲ 0.00%Market cap $16.93MP/E —$0.095$1.72
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| MCK McKesson Corporation Common Stock | $104.74B | 25.30 | $1,005 | ▲ 0.62% | $723.68$999 |
| COR Cencora Inc. Common Stock | $63.23B | 24.39 | $340.92 | ▼ 0.14% | $244.82$377.54 |
| CAH Cardinal Health Inc. Common Stock | $55.66B | 33.97 | $254.06 | ▲ 0.14% | $152.46$258.3 |
| HLF Herbalife Ltd. Common Shares | $1.19B | 9.24 | $14.6 | ▲ 0.21% | $7.56$20.4 |
| NUS Nu Skin Enterprises Inc. Common Stock | $251.98M | 4.30 | $5.14 | ▼ 1.34% | $4.45$11.67 |
| ZSTK ZeroStack Corp. Common Stock | $30.78M | — | $4 | ▼ 5.21% | $1.32$20.45 |
| HKPD Cellyan Biotechnology Co. Ltd Class A Ordinary Shares | $16.93M | — | $0.11 | ▲ 0.00% | $0.095$1.72 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- McKesson (MCK) Joins $5.8 Billion Option Care Health (OPCH) Acquisition. Is the Valuation Justified?Yahoo · 10/9/2026
- Deal Dispatch: Uber Buys ezCater For $2.3B, Skydance Takes Over Warner Bros., True Food Kitchen BankruptcyBenzinga · 10/9/2026
- Option Care Health (OPCH) Faces Legal Review Of Its Proposed TakeoverYahoo · 10/9/2026
- 1 Profitable Stock to Target This Week and 2 We IgnoreYahoo · 10/9/2026
- If You Invested $1000 in McKesson a Decade Ago, This is How Much It'd Be Worth NowYahoo · 10/9/2026
- Option Care Health (OPCH) Stock May Be Undervalued Despite The $5.8 Billion BuyoutYahoo · 10/9/2026
- How AI Adoption Could Supercharge McKesson (MCK)Yahoo · 10/8/2026
- Is McKesson (MCK) Outperforming Other Medical Stocks This Year?Yahoo · 10/8/2026
Insider Activity
Insider Actions →- Napoleon B. Rutledge Jr. · September 8, 2026 · Sale111 @ $891.45
- Bradley E. Lerman · August 10, 2026 · Sale301 @ $892.33
- Srinivasan Ramesh (NMN) · August 7, 2026 · Grant368
- Hinton James H. · July 22, 2026 · Grant277
- Lynne M. Doughtie · July 22, 2026 · Grant277
- Gerberding Julie L. · July 22, 2026 · Grant277
- Maria Martinez · July 22, 2026 · Grant277 @ $814.04
- Bradley E. Lerman · July 22, 2026 · Grant277
- Kevin M. Ozan · July 22, 2026 · Grant277
- Dominic J. Caruso · July 22, 2026 · Grant277 @ $814.04
- Deborah Dunsire · July 22, 2026 · Grant277
- Kathleen Wilson-Thompson · July 22, 2026 · Grant277 @ $814.04
- Webster Roy Dunbar · July 22, 2026 · Grant277
- Brian S. Tyler · July 7, 2026 · Sale8.5K @ $793.56
- Brian S. Tyler · June 17, 2026 · Sale8.5K @ $775.13
Institutional Ownership
March 31, 2026
- Total shares held
- 99.69M
- Total value held
- $82.65B
- Institutional holders
- 2009
- Unknown11.43M
- Unknown7.96M
- Unknown5.73M
- Unknown3.60M
- Unknown3.06M
- Unknown2.90M
- Unknown2.90M
- Unknown2.30M
- Unknown2.24M
- Unknown1.54M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
McKesson Re-Rated on M&A Momentum Amid Strong Performance
McKesson shares have risen while the broader market fell, driven by renewed analyst interest in the company's increased M&A efforts. This positive sentiment aligns with recent recognition from financial commentators who view the healthcare stock as a strong performer. The stock's strength is further supported by a high RSI, indicating significant recent buying pressure.
McKesson Re-Rated on M&A Momentum Amid Strong Performance. McKesson shares have risen while the broader market fell, driven by renewed analyst interest in the company's increased M&A efforts. This positive sentiment aligns with recent recognition from financial commentators who view the healthcare stock as a strong performer. The stock's strength is further supported by a high RSI, indicating significant recent buying pressure.